QVT Financial LP reduced its position in Intercept Pharmaceuticals Inc (NASDAQ:ICPT) by 33.6% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 13,854 shares of the biopharmaceutical company’s stock after selling 7,000 shares during the quarter. QVT Financial LP owned about 0.06% of Intercept Pharmaceuticals worth $809,000 as of its most recent filing with the Securities and Exchange Commission.
Several other institutional investors and hedge funds have also recently modified their holdings of the stock. Altrinsic Global Advisors LLC increased its holdings in Intercept Pharmaceuticals by 33.4% in the 4th quarter. Altrinsic Global Advisors LLC now owns 310,300 shares of the biopharmaceutical company’s stock valued at $18,128,000 after purchasing an additional 77,756 shares in the last quarter. Amalgamated Bank acquired a new stake in shares of Intercept Pharmaceuticals during the fourth quarter valued at about $209,000. Hudson Bay Capital Management LP acquired a new stake in shares of Intercept Pharmaceuticals during the fourth quarter valued at about $1,753,000. Senvest Management LLC grew its stake in shares of Intercept Pharmaceuticals by 66.3% during the fourth quarter. Senvest Management LLC now owns 970,926 shares of the biopharmaceutical company’s stock valued at $56,721,000 after acquiring an additional 387,136 shares in the last quarter. Finally, Spark Investment Management LLC grew its stake in shares of Intercept Pharmaceuticals by 43.9% during the fourth quarter. Spark Investment Management LLC now owns 181,110 shares of the biopharmaceutical company’s stock valued at $10,580,000 after acquiring an additional 55,210 shares in the last quarter. 74.27% of the stock is currently owned by institutional investors and hedge funds.
ICPT has been the topic of several research analyst reports. Deutsche Bank began coverage on shares of Intercept Pharmaceuticals in a research report on Tuesday, December 12th. They set a “buy” rating and a $106.00 price target on the stock. Credit Suisse Group set a $167.00 target price on shares of Intercept Pharmaceuticals and gave the stock a “buy” rating in a report on Monday, January 22nd. BidaskClub cut Intercept Pharmaceuticals from a “sell” rating to a “strong sell” rating in a report on Tuesday, January 16th. Wedbush reaffirmed a “buy” rating and set a $253.00 price target on shares of Intercept Pharmaceuticals in a report on Friday, January 5th. Finally, Citigroup set a $74.00 price target on Intercept Pharmaceuticals and gave the company a “hold” rating in a report on Friday, December 29th. Four investment analysts have rated the stock with a sell rating, ten have assigned a hold rating and ten have assigned a buy rating to the stock. Intercept Pharmaceuticals has an average rating of “Hold” and an average price target of $128.75.
Shares of ICPT stock traded down $1.52 on Monday, hitting $60.00. The company’s stock had a trading volume of 876,155 shares, compared to its average volume of 852,038. The firm has a market cap of $1,548.62, a PE ratio of -4.17 and a beta of -1.81. Intercept Pharmaceuticals Inc has a fifty-two week low of $51.05 and a fifty-two week high of $135.59. The company has a current ratio of 4.31, a quick ratio of 4.31 and a debt-to-equity ratio of 21.71.
Intercept Pharmaceuticals (NASDAQ:ICPT) last announced its earnings results on Wednesday, February 14th. The biopharmaceutical company reported ($4.43) EPS for the quarter, missing the consensus estimate of ($3.39) by ($1.04). The firm had revenue of $37.69 million during the quarter, compared to the consensus estimate of $39.01 million. Intercept Pharmaceuticals had a negative return on equity of 267.95% and a negative net margin of 275.18%. The business’s revenue was up 173.1% compared to the same quarter last year. During the same quarter last year, the business earned ($4.84) EPS. analysts forecast that Intercept Pharmaceuticals Inc will post -12.6 EPS for the current fiscal year.
TRADEMARK VIOLATION NOTICE: This story was first posted by Enterprise Leader and is the property of of Enterprise Leader. If you are reading this story on another website, it was illegally stolen and republished in violation of U.S. and international copyright & trademark legislation. The original version of this story can be viewed at https://theenterpriseleader.com/2018/04/02/qvt-financial-lp-cuts-stake-in-intercept-pharmaceuticals-inc-icpt.html.
Intercept Pharmaceuticals Company Profile
Intercept Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases. The Company’s product candidates have the potential to treat orphan and more prevalent diseases for which there are limited therapeutic solutions.
Receive News & Ratings for Intercept Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intercept Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.